COVID-19 感染患者的急性肢体缺血
该系统综述纳入 34 项研究共 540 例 SARS-CoV-2 感染合并急性肢体缺血患者,其中 199 例可分析。患者合并症比例较低,但汇总死亡率达 31.4%、截肢率达 23.2%;保守治疗较任何干预的死亡风险更高(OR 4.04,95%CI 1.075-15.197,P = .045)。
要点
- COVID-19 相关急性肢体缺血患者合并症少,但死亡率和截肢风险高。
- 保守治疗较任何干预的死亡风险更高(OR 4.04,P = .045)。
- 两种策略的截肢风险无差异(OR 0.977,P = .986)。
核心结论
- SARS-CoV-2 感染与包括急性肢体缺血在内的高血栓并发症风险相关。
- COVID 相关急性肢体缺血患者合并症发生率低,但死亡和截肢风险高。
- 保守治疗似乎比任何干预的死亡风险更高,但截肢风险相似。
研究设计与样本
- 系统检索 PubMed、Embase、Scopus 和 Cochrane Library 截至 2021 年 1 月在线发表的研究。
- 纳入报告 SARS-CoV-2 感染合并急性肢体缺血病例及早期结局(包括死亡率)的研究。
- 共纳入 34 项研究(19 项病例报告和 15 项病例系列/队列研究),总计 540 例患者,其中 199 例符合分析条件。
- 所有研究均发表于 2020 年。
- 患者平均年龄 61.6 岁(范围 39-84 岁;数据来自 32 项研究),78.4% 为男性(数据来自 32 项研究)。
主要发现
- 合并症发生率低:动脉高血压 49%(29 项研究)、糖尿病 29.6%(29 项研究)、血脂异常 20.5%(27 项研究)、慢性阻塞性肺疾病 8.5%(26 项研究)、冠心病 8.3%(26 项研究)、慢性肾病 7.6%(28 项研究)。
- 41.8% 的病例选择药物治疗作为一线治疗。
- 34 项研究的汇总死亡率为 31.4%(95%CI 25.4%-37.7%)。
- 34 项研究的汇总截肢率为 23.2%(95%CI 17.3%-29.7%)。
- 28 项研究的汇总临床改善率为 66.6%(95%CI 55.4%-76.9%),29 项研究的汇总再手术率为 10.5%(95%CI 5.7%-16.7%)。
关键数值与推荐
- 药物治疗较任何干预与更高的死亡风险相关(OR 4.04,95%CI 1.075-15.197,P = .045)。
- 药物治疗与任何干预的截肢风险无差异(OR 0.977,95%CI 0.070-13.600,P = .986)(数据来自 31 项研究)。
临床怎么用
- 对于 COVID-19 合并急性肢体缺血患者,应警惕高死亡和高截肢风险。
- 保守治疗可能增加死亡风险,临床决策时应考虑积极干预。
局限性
- 纳入研究以病例报告和病例系列为主,可能存在发表偏倚和异质性。
- 仅 199 例患者符合分析条件,样本量有限。
- 所有研究均发表于 2020 年,随访时间可能较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with thrombotic complications such as deep vein thrombosis or stroke. Recently, numerous cases of acute limb ischemia (ALI) have been reported although pooled data are lacking. METHODS: We systematically searched PubMed, Embase, Scopus, and the Cochrane Library for studies published online up to January 2021 that reported cases with SARS-CoV-2 infection and ALI. Eligible studies should have reported early outcomes including mortality. Primary endpoints included also pooled amputation, clinical improvement, and reoperation rates. RESULTS: In total, 34 studies (19 case reports and 15 case series/cohort studies) including a total of 540 patients (199 patients were eligible for analysis) were evaluated. All studies were published in 2020. Mean age of patients was 61.6 years (range, 39-84 years; data from 32 studies) and 78.4% of patients were of male gender (data from 32 studies). There was a low incidence of comorbidities: arterial hypertension, 49% (29 studies); diabetes mellitus, 29.6% (29 studies); dyslipidemia, 20.5% (27 studies); chronic obstructive pulmonary disease, 8.5% (26 studies); coronary disease, 8.3% (26 studies); and chronic renal disease, 7.6% (28 studies). Medical treatment was selected as first-line treatment for 41.8% of cases. Pooled mortality rate among 34 studies reached 31.4% (95% confidence interval [CI], 25.4%%-37.7%). Pooled amputation rate among 34 studies reached 23.2% (95% CI, 17.3%-29.7%). Pooled clinical improvement rate among 28 studies reached 66.6% (95% CI, 55.4%%-76.9%). Pooled reoperation rate among 29 studies reached 10.5% (95% CI, 5.7%%-16.7%). Medical treatment was associated with a higher death risk compared with any intervention (odds ratio, 4.04; 95% CI, 1.075-15.197; P = .045) although amputation risk was not different between the two strategies (odds ratio, 0.977; 95% CI, 0.070-13.600; P = .986) (data from 31 studies). CONCLUSIONS: SARS-CoV-2 infection is associated with a high risk for thrombotic complications, including ALI. COVID-associated ALI presents in patients with a low incidence of comorbidities, and it is associated with a high mortality and amputation risk. Conservative treatment seems to have a higher mortality risk compared with any intervention, although amputation risk is similar.
引用
- Galyfos G, Sianou A, Frountzas M, et al. Acute limb ischemia among patients with COVID-19 infection. J Vasc Surg. 2021. PMID: 34390791. doi:10.1016/j.jvs.2021.07.222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。